Hemerion

Executive Summary

Hemerion is a French clinical-stage healthtech company pioneering a novel drug-device combination therapy for brain cancer, specifically targeting glioblastoma (GBM). Founded in 2016 and based in Paris, the company integrates a photosensitizing drug with a photonic system to selectively destroy tumor cells during surgery, aiming to improve outcomes within the current standard of care. By leveraging photodynamic therapy (PDT), Hemerion's approach could address the high recurrence rates and poor prognosis of GBM, offering a differentiated solution that combines surgical precision with targeted cytotoxicity. The company's lead program is in early-to-mid-stage clinical development, and it has the potential to become a key player in the neuro-oncology space. With a focus on integrating its therapy into existing surgical workflows, Hemerion seeks to minimize additional procedural complexity while maximizing efficacy. The technology holds promise not only for GBM but also for other solid tumors where intraoperative illumination is feasible. As a private company, Hemerion is poised for upcoming clinical milestones and regulatory engagements that could validate its approach and unlock partnership or financing opportunities.

Upcoming Catalysts (preview)

• H2 2026Phase 2/3 interim data readout for GBM40% success
• Q3 2026FDA Orphan Drug Designation70% success
• Q1 2027Strategic partnership with a major oncology player30% success